Comparing Addition of Radiotherapy in EGFR- and ALK-Positive NSCLC With Brain Metastases: Are We Evaluating the Optimal End Point?
Comparing Addition of Radiotherapy in EGFR- and ALK-Positive NSCLC With Brain Metastases: Are We Evaluating the Optimal End Point? / Nardone V.; Correale P.; Mutti L.; Desideri I.; Romeo C.; Pastina P.; Tagliaferri P.; Caraglia M.; Reginelli A.; Pirtoli L.; Cappabianca S.. - In: JOURNAL OF THORACIC ONCOLOGY. - ISSN 1556-0864. - ELETTRONICO. - 17:(2022), pp. e10-e12. [10.1016/j.jtho.2021.09.019]
Comparing Addition of Radiotherapy in EGFR- and ALK-Positive NSCLC With Brain Metastases: Are We Evaluating the Optimal End Point?
Desideri I.;
2022
Abstract
Comparing Addition of Radiotherapy in EGFR- and ALK-Positive NSCLC With Brain Metastases: Are We Evaluating the Optimal End Point?
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
1-s2.0-S1556086421032573-main.pdf
Accesso chiuso
Tipologia:
Pdf editoriale (Version of record)
Licenza:
Tutti i diritti riservati
Dimensione
146.68 kB
Formato
Adobe PDF
|
146.68 kB | Adobe PDF | Richiedi una copia |
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
